|
Originally published In Press as doi:10.1074/jbc.M105202200 on September 24, 2001
J. Biol. Chem., Vol. 276, Issue 47, 43597-43603, November 23, 2001
Internalin B Activates Nuclear Factor- B via Ras,
Phosphoinositide 3-Kinase, and Akt*
Ashley
Mansell §,
Nadia
Khelef¶,
Pascale
Cossart¶ , and
Luke A. J.
O'Neill **
From the Department of Biochemistry and Biotechnology
Institute, Trinity College, Dublin 2, Ireland and ¶ Unité
des Interactions Bactéries-Cellules, 25-28 rue du Dr. Roux,
Institut Pasteur, Paris Cedex 15, France
Received for publication, June 6, 2001, and in revised form, September 12, 2001
 |
ABSTRACT |
Internalin B (InlB), a 630-amino acid
protein loosely attached to the surface of Listeria
monocytogenes, participates in the entry of the bacterium into
mammalian cells. This process requires the activation of
phosphoinositide (PI) 3-kinase by InlB. Previously, we demonstrated
that InlB activates the transcription factor Nuclear Factor- B in
murine J774 macrophage-like cells, an event that also requires PI
3-kinase. Here we have further investigated this phenomenon. InlB
activated the small G-protein Ras in J774 cells. Inhibition of Ras with
the farnesyltransferase inhibitor manumycin A inhibited NF- B
activation and the recruitment of the p85 subunit of PI 3-kinase,
implying that Ras is required for PI 3-kinase activation. InlB also
activated the PI 3-kinase downstream effector, Akt, as assessed by
increased phosphorylation of Akt on serine 473. Transfection of Hep2
cells with dominant negative Ras N17 or dominant negative Akt inhibited
the induction of a reporter gene linked to the interleukin-8 promoter
by InlB. Furthermore, the Ras inhibitor manumycin A, the PI 3-kinase
inhibitor LY294002, and an Akt inhibitor all blocked the induction of
interleukin-8 by InlB. Our study is the first report of a bacterial
product activating a pathway involving Ras, PI 3-kinase, and Akt, which leads to NF- B activation. This process could be involved in
host defense or the inhibition of apoptosis during infection.
 |
INTRODUCTION |
Listeria monocytogenes is a Gram-positive,
food-borne, intracellular bacterium that causes meningitis,
septicaemia, abortion, and peritoneal infections. It is capable of
infecting both nonprofessional and professional phagocytic cells. The
invasion process can be divided into two steps: attachment to the host
cell membrane, followed by internalization. Once internalized, the
bacterium rapidly lyses the phagocytic vacuole, liberating it into the
cytosol. The bacterium quickly starts coating itself with actin
filaments, propelling it through the cytosol where it is able to
invaginate the plasma membrane of neighboring cell, thus avoiding the
immune response (reviewed in Refs. 1-4).
Two proteins, internalin A
(InlA)1 and internalin B
(InlB), have been found to be crucial in mediating the internalization of Listeria into nonprofessional phagocytes (2, 4). It has been suggested that the different characteristics of each protein determines the efficiency of internalization into specific cell types
(4).
InlB is a 630-amino acid protein consisting of eight leucine-rich
repeats, each comprising 22 amino acids with high homology with those
of InlA, an inter-region containing two repeats of ~70 amino acids,
and a 232-amino acid carboxyl-terminal region consisting of tandem
repeats each of ~80 amino acids, which begins with the motif GW (5).
InlB only loosely associates with the cell surface of Listeria
monocytogenes via the GW-containing region and appears to be
partly released during infection. It has been shown to confer
invasiveness to latex beads and noninvasive Listeria species
when surface-associated (6, 7). The NH2-terminal leucine-rich repeats are critical for entry (8). Its structure has been
recently elucidated (9).
Entry of L. monocytogenes is an active process, and part of
the mechanism involves activation of phosphoinositide (PI) 3-kinase, because entry is blocked by chemical and genetic inhibition of this
enzyme (10). InlB appears to be responsible for PI 3-kinase activation
and also induces the recruitment of the mammalian adaptor proteins Shc,
Cbl, and Gab-1. Gab-1 in turn has been shown to recruit the p85 subunit
of PI 3-kinase (11).
The first receptor described for InlB, gC1q-R, is one of the receptors
for the complement protein C1q (12). It does not contain a
transmembrane region or glycosylphosphatidylinositol linkage sequence.
This would suggest that gC1q-R is acting as a co-receptor for a
transmembrane signaling protein capable of initiating signal
transduction. A possible candidate has been described by Shen et
al. (13), who demonstrated that c-Met, the tyrosine kinase
receptor for hepatocyte growth factor (HGF), or "scatter factor,"
can bind InlB. Similar to InlB, HGF has been shown to activate PI
3-kinase, and InlB can induce epithelial cell scattering. Both InlB
(14) and HGF (15) also activate the transcription factor NF- B. For
InlB, this may be a host defense response, because NF- B regulates
the expression of many inflammatory genes. Alternatively, NF- B
activation by InlB may be a mechanism whereby L. monocytogenes inhibits apoptosis in infected cells, because of the
anti-apoptotic effect of NF- B (16-18).
We have shown that the mechanism of NF- B activation by InlB in J774
macrophages involves PI 3-kinase (14). Here, we have found that,
similar to HGF, InlB activates the low molecular weight G-protein Ras.
PI 3-kinase activation occurs downstream of Ras and leads to the
activation of Akt. Our study therefore identifies signaling processes
initiated by InlB, which are involved in NF- B activation.
 |
EXPERIMENTAL PROCEDURES |
Materials--
InlB was purified as described previously (7).
Anti-pan-Ras antibody was purchased from Oncogene Research Products
(Cambridge, MA), whereas the mouse monoclonal antibody, which
recognizes the epitope between amino acids 21 and 48 of I B , was a
kind gift from Prof. Ron Hay (St. Andrews, United Kingdom). Manumycin A (Calbiochem), LY294002 (Sigma), and
1L-6-hydroxymethyl-chiro-inositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate]
(Alexis Biochemicals) were dissolved in dimethyl sulfoxide. Phospho-Akt
and Akt antibodies were obtained from New England Biolabs. Vectors
pPL-IL-8-pLuc and pTK-rLuc were kind gifts from Dr. E. Kiss-Toth
(University of Sheffield, Sheffield, United Kingdom). The expression
vectors encoding dominant negative Ras N17 (described previously; Ref. 19), empty vector Rous sarcoma virus, and the expression vector encoding amino acids 1-149 of human c-Raf1 in pGex-KG, i.e.
glutathione S-transferase (GST)-Ras binding domain (RBD),
were kind gifts of Dr. Doreen Cantrell (Imperial Cancer Research Fund,
London, United Kingdom). The expression vector encoding dominant
negative Akt was donated by Dr. Stephan Ward (Bath University, Bath,
United Kingdom). The 22-base pair oligonucleotide, 5'-AGT TGA
GGG GAC TTT CCC AGG
C-3', containing the NF- B consensus sequence (underlined) and T4
polynucleotide kinase kit were from Promega Corp.
[ -32P]ATP (3000 Ci/mol) and the enhanced
chemiluminescence ECL reagent were both from Amersham Pharmacia
Biotech. Poly(dI-dC) was supplied by Amersham Pharmacia Biotech
(Uppsala, Sweden).
Cell Culture--
The murine macrophage-like cell line J774 was
kindly provided by Prof. Kingston Mills (National University of
Ireland, Maynooth, Ireland) and was grown in 10% heat-inactivated
fetal calf serum (FCS) (Sigma) in RPMI 1640 (Sigma), which was
supplemented with 2 mM L-glutamine (Life
Technologies, Inc.), 5% CO2. The human epithelial cell
line Hep2 were grown in 10% FCS, Dulbecco's modified Eagle's medium
(Sigma), 2 mM L-glutamine at 5%
CO2.
Ras Activation Assay--
J774 cells were cultured at 5 × 106 in 100-mm (10 ml) culture dishes for 24 h in 10%
FCS/RPMI 1640, then an additional 24 h in serum-free RPMI 1640, prior to InlB stimulation (500 ng/ml). Cells were washed with ice-cold
PBS, and lysates extracted with Ras lysis buffer (50 mM
Hepes, pH 7.4, 10 mM NaF, 10 mM iodoacetamide, 75 mM NaCl, 1% Nonidet P-40, 10 mM
MgCl2, 1 mM PMSF, 1 mM sodium vanadate, 1 mg/ml -glycerol phosphate) for 20 min on ice. Equal protein amounts were incubated for 2 h at 4 °C with C-Raf-1 RBD (residues 1-149) precoupled to glutathione-agarose beads (50% slurry). Only activated Ras-GTP will bind to beads, so that activated protein can be pelleted with beads by centrifugation at 2500 × g, 3 min, 4 °C. Beads were boiled in SDS-PAGE sample
buffer for 5 min and separated on 15% SDS-PAGE. Proteins were
transferred to nitrocellulose, immunoblotted with Ras antibody and
anti-mouse IgG peroxidase-conjugated antibody, and visualized by
chemiluminescence. Equal protein loading was also determined by
staining transferred PAGE gel with Coomassie Blue stain.
Nuclear Extract Preparation and Electrophoretic Mobility
Shift Assays--
Assays were conducted as described previously (14);
briefly, J774 were seeded at 1 × 105 cells/ml in
six-well plates. Relevant concentrations of proteins were added to
cells and incubated for 1 h at 37 °C.
Nuclear extracts were prepared by aspiration of media from cells and
replacement with ice-cold hypotonic buffer. The subsequent cell pellet
was on ice for 10 min. Nuclear-associated proteins were extracted and
maintained on ice for 20 min. Following centrifugation, the supernatant
was mixed with storage buffer and used immediately, or frozen at
20 °C. Protein concentrations were determined using the method of
Bradford (20) and extracts stored at 20 °C.
In the electrophoretic mobility shift assay, nuclear extracts were
incubated with 10,000 cpm of a 22-base pair DNA fragment oligonucleotide containing the NF- B consensus sequence previously labeled with [ -32P]ATP. Incubation was for 30 min, in
the presence of poly(dI-dC) and 10× binding buffer. Incubated mixtures
were subjected to electrophoresis on native 5% (w/v) polyacrylamide
gels, which were subsequently dried and autoradiographed.
I B Immunoblot Analysis--
Murine macrophage-like cells
J774 were seeded at 5 × 104 cells/ml in six-well
plates (3 ml volume), 48 h prior to stimulation and incubated at
37 °C, 5% CO2. InlB (500 ng/ml) was added, and stimulation was terminated at relevant time points by aspiration of
culture media and subsequent addition of 1 ml of ice-cold PBS. After
aspiration of PBS from the cells, 100 µl of ice-cold radioimmune precipitation buffer (1% Igepal CA-630, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate in PBS, containing 10 mg of PMSF, 7 µg of
aprotinin, and 1 mM sodium vanadate) was added. Plates were shaken on ice for 10 min and cell scraped to ensure lysis. Following further disruption of cells by passage through a 21-gauge needle (10 strokes), an additional 0.1 mg/ml PMSF was added to the samples, which
were incubated for 45 min. Samples were then centrifuged for 10 min at
13,200 × g at 4 °C, and the supernatant was removed from the cell debris and assayed for protein by Bradford method (20).
Equal amounts of protein (4 µg) were resolved by SDS-PAGE and
transferred to nitrocellulose, where I B immunoblot was carried out as described previously (21).
p85 Recruitment Assay--
Recruitment assays for p85 were
performed as described previously (8). Cells were seeded at
7 × 104 cells/ml in 100-mm culture dishes 48 h prior
to stimulation with InlB (500 ng/ml). Inhibitors were preincubated with
cells for indicated times where necessary. Cells were washed with cold
PBS and then lysed in 1 ml of ice-cold immunoprecipitation buffer for
10 min. Lysates were assayed for protein (20) and precleared with 30 µl of protein A-Sepharose beads (Sigma) for 30 min at 4 °C. The
beads were pelleted and the lysates removed. Lysates were incubated
with anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology Inc.)
for 120 min at 4 °C. The beads were pelleted, the lysate removed,
and the beads washed another 3 times. Beads were resuspended in
SDS-PAGE sample buffer, boiled for 5 min, centrifuged to remove beads,
and then subjected to electrophoresis (7% SDS-PAGE). Proteins were
transferred to nitrocellulose, probed with anti-p85 polyclonal
antibody, detected with rabbit immunoglobulin G, and visualized with
chemiluminescence system (Amersham Pharmacia Biotech).
Akt Immunoblot Analysis--
J774 cells were cultured at 5 × 104/ml in 100-mm dishes for 48 h prior to
stimulation in serum-free RPMI 1640. Cells were stimulated with 500 ng/ml InlB for the indicated times. Cells were aspirated, washed with
ice-cold PBS, and lysed with 100 µl of SDS-PAGE sample buffer. The
lysate was sonicated, boiled for 5 min, and centrifuged for 10 min at
13,200 × g, to remove nuclei and cell debris. Proteins were separated by electrophoresis (SDS-PAGE, 10%), transferred to
nitrocellulose, and immunoblotted with antibodies against
Phospho-Akt(Ser-473) antibody (New England Biolabs). Secondary antibody
rabbit immunoglobulin G was applied and detected by chemiluminescence
according to the manufacturer's recommendations (Pierce).
Nitrocellulose membranes were stripped of previous antibodies (washed
three times with 50 mM glycine, pH 2.0) and reprobed with
Akt antibody (New England Biolabs) to determine protein loading.
Transient Transfections--
Hep2 cells (1.5-2 × 104) were seeded into 96-well tissue culture plates 24 h prior to transfection. Transfections were preformed with SuperFect
(Qiagen) according to manufacturer's instructions; each well receiving
500 ng of pPL-IL-8 (which comprises the IL-8 promoter linked to
luciferase, which requires NF- B for its activation) (23), 100 ng of
pTK-rLuc for normalization of transfection efficiency, indicated
amounts of either dominant negative Akt or Ras N17 for relevant
experiments, and pRSV empty vector was used to maintain constant
amounts of DNA dose. After transfection (2 h incubation), cells were
washed and 100 ml of fresh medium added. Cells were transfected in
triplicate for each sample. Twenty-four hours later, cells were
pretreated, then stimulated with 500 ng/ml InlB, and incubated for an
additional 24 h. Cells were washed with PBS and measured using the
dual luciferase system (Promega) as recommended by the manufacturer.
Normalized IL-8-promoter-driven activity is the ratio of firefly to
Renilla luciferase activity.
IL-8 ELISA--
Hep2 cells were seeded in 96-well plates (1 × 104 cells in 200 µl) and 24 h later stimulated
with 500 ng/ml InlB for 24 h with or without 45 min of
pretreatment with inhibitors (manumycin A, LY294002, and Akt inhibitor)
diluted in Dulbecco's modified Eagle's medium. Cell supernatants were
harvested and assayed for IL-8 by ELISA using the DuoSet ELISA
development system for human IL-8 (R&D Systems, Minneapolis, MN),
according to manufacturer's instructions.
Statistical Analysis--
Significance was evaluated using
Student's t test for unpaired data.
 |
RESULTS |
InlB Induces Activation of the Small G-protein Ras--
We have
previously shown PI 3-kinase to be involved in InlB-mediated activation
of NF- B (14). We first investigated whether the small G-protein Ras
was involved in this response. As shown in Fig.
1A, treatment of J774 cells
with 500 ng/ml InlB induced an increase in GTP-bound Ras in a
time-dependant manner, as assessed by immunoblotting samples for Ras
immunoprecipitated from lysates using the Ras-binding domain for Raf,
which only recognizes GTP-bound Ras. Maximal activation was detected
after 1 min of stimulation (lane 2), and the response
continued until 5 min after stimulation (lane 5). The effect
was transient, returning to basal activation levels 15 min after
stimulation (lane 5).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
InlB induces activation of the small
G-protein Ras, which is required for NF- B
activation. A, 5 × 106 J774 cells
were grown for 24 h and serum-starved for 24 h prior to
stimulation with 500 ng/ml InlB in serum-free media. Activated Ras
present in cell lysates was precipitated, as described under
"Experimental Procedures." Proteins were separated on 15%
SDS-PAGE, transferred to nitrocellulose, and immunoblotted with
anti-pan-Ras antibody. Identical results were obtained in two
additional experiments. Lower band shows GST-RBD
and confirms equal protein loading as assayed by Coomassie Blue
staining of the proteins remaining on the SDS-PAGE after transfer.
B, 5 × 104 cells/ml J774 cells were grown
for 48 h, pretreated for 60 min with manumycin A (2-10
µM), and stimulated with 200 ng/ml InlB for 60 min.
NF- B activation was determined by electrophoretic mobility shift
assay as described under "Experimental Procedures." NF- B-DNA
complexes are shown. Result is representative of three independent
experiments. C, 5 × 104/ml J774 cells were
grown for 48 h, pretreated with manumycin A or media as control
for 60 min, and stimulated with 500 ng/ml InlB for 60 min. Equal
amounts of protein from cell lysates were separated on 10% SDS-PAGE,
transferred to nitrocellulose, and immunoblotted with monoclonal
antibody against I B . Identical re- sults were obtained in an additional experiment. D,
Hep2 cells (1.5-2 × 104) were transiently
transfected with IL-8-luciferase (500 ng),
TK-Renilla-luciferase, and indicated amounts of Ras N17 for
24 h prior to stimulation with InlB (500 ng/ml, 24 h).
Cell extracts were analyzed for luciferase activity. Readings are
normalized for each sample as expressed IL-8-luciferase over
constitutively expressed TK-Renilla-luciferase and plotted
as -fold stimulation. Results are mean ± S.D. of triplicate
samples and are representative of two additional experiments.
E, Hep2 cells were seeded at 1 × 104
cells/200 µl in 96-well dishes. After 24 h, cells were
pretreated with 0-100 nM manumycin A for 45 min before
stimulation with 500 ng/ml InlB. Cells were incubated for another
24 h and cell supernatants collected and analyzed for IL-8 by
ELISA. Results are mean ± S.D. of triplicate samples. An
identical result was obtained in an additional experiment.
|
|
A role for Ras in mediating InlB-induced NF- B activation was tested
by using the Ras inhibitor manumycin A, which is a potent and selective
farnesyltransferase inhibitor (24). Fig. 1B illustrates that
pretreatment of J774 cells with manumycin A inhibited InlB-mediated NF- B activation in a dose-dependent manner, with 10 µM abolishing the effect (lane 5).
As shown in Fig. 1C, manumycin A also prevented InlB-induced
degradation of I B . InlB induces I B degradation from 15 min, most of the I B being degraded by 60 min. Manumycin A inhibited this response (compare lanes 8-10 with lanes
3-5). We also tested whether Ras N17, a dominant negative mutant
of Ras, could block induction of a reporter gene, luciferase, under the
control of the IL-8 promoter, which is NF- B-dependent.
These experiments were carried out in the cell line Hep2, because we
found that J774 cells could not be transfected to a high enough
efficiency. We have previously shown Hep2 cells to be responsive to
InlB in terms of NF- B activation. InlB induced a 2-2.5-fold
increase in luciferase activity. This was the maximum response in these cells (data not shown). Transfection of Hep2 cells with a plasmid encoding Ras N17 inhibited this response, with 50 ng of plasmid abolishing the effect. Because the stimulation of the IL-8 promoter was
somewhat weak, and to examine another NF- B-dependent
response, we measured induction of IL-8 by InlB and examined the effect of manumycin A on this response. As shown in Fig.
1E, InlB-induced an ~8-fold stimulation
of IL-8 expression over nonstimulated cells after 24 h of
stimulation. Manumycin A inhibited this effect in a
dose-dependent manner, with 100 nM manumycin A
abolishing the effect. Taken together, these results imply that Ras is
involved in mediating NF- B activation via InlB.
InlB Induces Recruitment of the p85 Subunit of PI
3-Kinase--
Fig. 2A
demonstrates how the treatment of J774 cells with the PI 3-kinase
inhibitor 50 µM LY294002 inhibited the induction of
I B degradation by InlB (compare lanes 6 and
7 with lanes 3 and 4). As shown in
Fig. 2B, InlB induced the rapid recruitment of the p85
subunit of PI 3-kinase to a complex containing tyrosine-phosphorylated proteins in J774 cells. For this, cell lysates prepared from
InlB-stimulated J774 cells were immunoprecipitated with an
anti-phosphotyrosine antibody, then blotted with anti-p85 polyclonal
antibody as described by Braun et al. (8). Recruitment was
observed 1 min after stimulation (lane 2), reaching a
maximum between 5 and 15 min (lanes 3 and 4), and
began declining at 30 min (lane 5). InlB has been shown previously to stimulate p85 recruitment in Vero cells after 1 min,
decreasing rapidly thereafter (8, 11). Vero cells were therefore used
as a positive control, a sample from cells treated for 1 min with InlB
being shown (lane 7).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
PI 3-kinase is involved in InlB-mediated
NF- B activation. 5 × 104 J774 cells were grown for 48 h, pretreated for 20 min with LY294002 or medium alone, and stimulated with InlB (500 ng/ml)
for indicated times. Cells were lysed. Equal amounts of proteins were
separated by 10% SDS-PAGE, transferred to nitrocellulose, and
immunoblotted for I B . Results are representative of three
independent experiments. B, 7 × 104 J774
or Vero cells were grown for 48 h prior to stimulation with 500 ng/ml InlB for the stated times. Protein extracts from cell lysates
were immunoprecipitated with -phosphotyrosine antibody 4G10,
separated by 10% SDS-PAGE, transferred to nitrocellulose, and
immunoblotted with polyclonal -p85 antibody. Results are
representative of three independent experiments. C, Hep2
cells (1.5-2.0 × 104) were transfected with reporter
plasmids for IL-8-luciferase and TK-Renilla-luciferase for
24 h, pretreated with LY294002, and stimulated with InlB (500 ng/ml, 24 h). Luciferase activity was assayed for each sample.
Readings are normalized for each sample as expressed IL-8-luciferase
over constitutively expressed TK-Renilla-luciferase and
plotted as -fold stimulation. Results are means ± S.D. for
triplicate determinations. An identical result was obtained in an
additional experiment. D, Hep2 cells were seeded at 1 × 104 cells/200 µl in 96-well dishes. After 24 h,
cells were pretreated with 0-100 µM LY294002 for 20 min
before stimulation with 500 ng/ml InlB. Cells were incubated for
another 24 h and cell supernatants collected and analyzed for IL-8
by ELISA. Results are mean ± S.D. of triplicate samples. An
identical result was obtained in an additional experiment.
|
|
Intriguingly, pretreatment of J774 cells with LY294002, prior to
stimulation with InlB, blocked the recruitment of p85 (data not shown).
LY294002 is known to act as an inhibitor of the p110 catalytic subunit
of PI 3-kinase by covalently binding to the subunit and rendering it
catalytically inactive (25). The basis for this inhibition is unclear,
but suggests that p85 recruitment depends on p110.
We next investigated whether PI 3-kinase was also involved in
NF- B-dependent transcriptional activity induced by InlB.
Again we used the epithelial cell line Hep2. As shown in Fig.
2C, InlB induced a 2.5-fold increase in the expression of
the luciferase reporter gene. LY294002 inhibited this response, with
100 µM having a maximal effect. To further support this
finding, LY294002 was again tested against InlB-induced IL-8 protein
expression in Hep2 cells. Fig. 2D demonstrates that LY294002
abrogated InlB-induced IL-8 expression in a dose-dependent
manner, with 50 µM LY294002 abolishing the effect of
InlB.
These results confirm that PI 3-kinase is involved in the activation of
NF- B by InlB.
InlB Mediates Phosphorylation of Akt--
We next wished to
determine whether InlB was able to activate protein kinase B/Akt, a
critical downstream target of PI 3-kinase (26, 27) that has been shown
to transiently associate with, and activate, the I B kinase complex
leading to NF- B activation (28-30). As shown in Fig.
3A, InlB induced
phosphorylation of Akt as assessed by immunoblotting whole cell lysates
with a phosphospecific antibody that recognizes Akt only when
phosphorylated on Ser473. Increased phosphorylation was observed within
15 min (lane 3) and was optimal 30 min after stimulation
(lane 4), returning to basal phosphorylation levels at 45 min (lane 5). Pretreatment of the cells with the PI 3-kinase
inhibitor LY294002, as shown in Fig. 3B, blocked the effect
(compare lanes 6-9 with lanes
2-5).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Akt is involved in InlB-mediated NF- B
activation. 7 × 105 J774 cells were grown in
serum-free media, 48 h prior to stimulation with 500 ng/ml InlB
for indicated times. Protein extracts from cell lysates were separated
by 10% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with
anti-phospho-Akt antibody (Ser-473). Membranes were stripped and
further probed with anti-Akt antibody to determine equal protein
loading for each sample. Identical results were obtained from an
additional experiment. B, 7 × 105 J774
cells were grown for 48 h in serum-free medium, treated or not
with 50 µM LY294002 for 20 min prior to InlB (500 ng/ml)
stimulation. Proteins extracted from cell lysates were separated by
10% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with
anti-phospho-Akt antibody. Membranes were stripped and further
immunoblotted for endogenous Akt to determine equal loading. Identical
results were obtained from an additional experiment. C, Hep2
cells (1.5-2 × 104) were transiently transfected
with IL-8-luciferase (500 ng), TK-Renilla-luciferase, and
indicated amounts of dominant negative mutant Akt, 24 h prior to
stimulation with InlB (500 ng/ml, 24 h). Extracts were analyzed
for luciferase activity. Readings are normalized for each sample as
expressed IL-8-luciferase over constitutively expressed
TK-Renilla-luciferase and plotted as -fold stimulation.
Results are mean ± S.D. of triplicate samples. An identical
result was obtained in an identical experiment. D, Hep2
cells were seeded at 1 × 104 cells/200 µl in
96-well dishes. After 24 h, cells were pretreated with 0-20
µM 1L-6-hydroxymethyl-chiro-inositol
2-[(R)-2-O-methyl-3-O-octadecylcarbonate]
for 30 min before stimulation with 500 ng/ml InlB. Cells were incubated
for another 24 h and cell supernatants collected and analyzed for
IL-8 by ELISA. Results are mean ± S.D. of triplicate samples.
Data indicate significant differences (*, p = 0.004;
**, p = 0.005) when compared with control samples. An
identical result was obtained in an additional experiment.
|
|
We next tested the effect of a plasmid encoding a dominant
negative mutant of Akt on activation of the IL-8 promoter. As can be
seen in Fig. 3C, transient transfection of the dominant
negative mutant inhibited the response induced by InlB, with 50-100 ng of plasmid reducing the effect. To further investigate Akt involvement in InlB-mediated NF- B transcriptional activation, the effect of the
recently described Akt inhibitor
1L-6-hydroxymethyl-chiro-inositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate]
(31, 32) on InlB-mediated IL-8 gene expression was assayed by ELISA in
Hep2 cells. As shown in Fig. 3D,
1L-6-hydroxymethyl-chiro-inositol
2-[(R)-2-O-methyl-3-O-octadecylcarbonate] inhibited the expression of IL-8 in a dose-dependent
manner, with 10 and 20 µM both having a significant
effect, reducing expression by up to 50%. These results indicate that
Akt activation is required for NF- B activation by InlB.
Ras Activation by InlB Occurs Upstream of PI 3-Kinase--
We next
wished to determine the relationship between Ras and PI 3-kinase in
InlB-mediated signaling. J774 cells were pretreated with LY294002 for
20 min, stimulated with 500 ng/ml of InlB, and Ras activation
determined at a time range of 0-2.5 min. As can be seen in Fig.
4A, LY294002 had no effect on
InlB-induced Ras activation. Similar to nontreated cells, Ras
activation occurred at 2.5 min of stimulation, which was also evident
in LY294002-treated cells.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 4.
InlB-mediated NF- B
activation involves Ras and Akt. A, J774 (5 × 106) cells were grown for 24 h in 10% FCS/RPMI,
serum-starved for 24 h, treated for 20 min with serum-free media
containing or not containing 50 µM LY294002 prior to InlB
stimulation (500 ng/ml). Equal protein amounts from cell lysates were
incubated for 2 h with GST-RBD coupled to glutathione-agarose
beads. Proteins were separated on 15% SDS-PAGE, transferred to
nitrocellulose, and immunoblotted with anti-pan-Ras antibody.
Lower band shows GST-RBD and confirms equal
protein loading as assayed by Coomassie Blue staining of the proteins
remaining on the SDS-PAGE after transfer. Identical results were
obtained in an additional experiment. B, 7 × 105 J774 cells were grown for 48 h, treated with
manumycin A for 60 min prior to stimulation with 500 ng/ml InlB.
Proteins from cell lysates were immunoprecipitated with
-phosphotyrosine antibody 4G10, separated on 7% SDS-PAGE,
transferred to nitrocellulose, and subsequently immunoblotted with
-p85 antibody. Nitrocellulose membranes were stained with Ponceau S
to confirm equal loading. Identical results were obtained in an
additional experiment.
|
|
To further support this, we wished to determine whether the
farnesyltransferase inhibitor manumycin A could block recruitment of
p85. J774 cells were pretreated with 5 µM manumycin A for
60 min, stimulated with 500 ng/ml InlB, and then analyzed for p85 recruitment. Fig. 4B illustrates that manumycin A was able
to totally abrogate the recruitment of p85 to the InlB-mediated
phosphorylated complex (compare lanes 6 and 7 with lanes 2 and 3). This strongly suggests that
Ras activation occurs upstream of PI 3-kinase in InlB-induced
signaling, a conclusion supported by the earlier finding that the
timing of Ras activation by InlB precedes recruitment of p85 to the
signaling complex.
 |
DISCUSSION |
In this study we have analyzed the signaling pathway activated by
the L. monocytogenes protein InlB, which culminates with the
activation of NF- B. InlB had been shown previously to activate PI
3-kinase (10, 11), a response required for internalization of L. monocytogenes (7). Here, we have shown that in J774 macrophages the activation of PI 3-kinase occurs downstream of Ras activation, and
that Akt is activated following PI 3-kinase. Our results are the first
demonstration of a bacterial protein utilizing Ras, PI 3-kinase, and
Akt as signaling mediators that result in NF- B activation and
suggests that PI 3-kinase-mediated internalization may require Ras.
During the course of this research, it was demonstrated that c-Met, the
heterodimeric receptor for HGF, was the mammalian receptor for InlB
(13, 33). The first reported receptor for InlB was gC1q-R (12), a
protein that binds the complement protein C1q. This protein lacks a
transmembrane domain and also lacks an identifiable cytoplasmic region.
Its role in InlB signal transduction remains unclear, although it is
possible that it interacts with Met. The identification of Met as a
receptor for InlB provides a molecular explanation for previously
reported InlB signals. These signals include recruitment of Gab-1 and
Cbl to phosphotyrosines. The binding of HGF to Met triggers
dimerization and autophosphorylation of the receptor, instigating
recruitment of adaptor proteins, and initiating several different
signaling pathways, including recruitment of Gab-1, Cbl, p85, and
Grb-2, this last signal leading to Ras activation (34-36). HGF also
activates NF- B (15), although the post-receptor signals involved are
yet to be determined. Our finding that InlB activates NF- B via Ras
and Akt adds two further common signals to the list mediated by InlB
and HGF, further strengthening the role of Met in InlB signal transduction.
Our data suggest that Ras is required for PI 3-kinase activation, as
indicated by the inhibitory effect of manumycin A on p85 recruitment.
Ireton et al. (11) have demonstrated that InlB induces the
formation of Gab-1.p85 complexes in Vero cells. This may be another
means of activating PI 3-kinase. Ras, however, may not play a role in
this response in the cells.
It has been suggested that Ras activation of PI 3-kinase is required
for optimal response to growth factors, where Ras-GTP activation
combined with recruitment of p85 to tyrosine-phosphorylated residues on
growth factor receptors synergize to give full activation of PI
3-kinase (37, 38). Our finding that Ras acts upstream of PI 3-kinase,
combined with the Ireton et al. findings (11) of Gab-1·p85
complex recruitment to InlB-mediated phosphotyrosines, suggests that
this interaction could be involved in this response.
Our study also demonstrates that, for Ras, PI 3-kinase and the
downstream effector of PI 3-kinase, Akt, are involved in the pathway
for NF- B activation. Akt has been shown to activate the I B kinase
complex by inducing the phosphorylation of IKK at threonine position
23 (Thr-23) (30), a site claimed to be essential for IKK activation
(39). This action causes the phosphorylation of I B, leading to the
release of NF- B. This pathway may mediate the effect of InlB here.
The role of Akt in the activation of the IKK complex is controversial,
however, and may be cell type-specific. Akt has been shown to promote
transactivation by the p65 subunit of NF- B (40, 41), thus allowing
gene transcription. This process also occurs downstream of Ras. Our
data would suggest that Akt might be having a direct effect upon IKK,
as inhibition of Ras and PI 3-kinase by specific inhibitors blocked
I B degradation. A dominant negative mutant of Akt also blocked
NF- B-driven gene transcription, possibly pointing to a role in the
pathway of transactivation.
Our evidence that Ras, PI 3-kinase, and Akt are required for NF- B
activation, was supported by data demonstrating that dominant negative
Ras N17, LY294002 and dominant negative Akt blocked induction of a
reporter gene luciferase, linked to the IL-8 promoter, which is
NF- B-dependent. The stimulation of the promoter by InlB,
although weak, was consistently observed, and the signaling inhibitors consistently blocked induction. The basis for the weakness in the
response is not clear. To confirm this result, we measured IL-8 protein
production. This gave a much stronger response to InlB. We again tested
LY294002 in the response and found it to be inhibitory. We were unable
to test dominant negative mutants in this assay, because it is not
transfection-based, and Hep2 cells are not transfectable to a high
enough efficiency to ensure that enough cells in the population would
be susceptible to inhibition. Therefore, we again tested the Ras
inhibitor manumycin A and a newly described inhibitor of Akt. Both
abolished the effect of InlB on IL-8 production, confirming the result
obtained in the IL-8 promoter assay, and providing additional support
for Ras and Akt as possible signal transducers for InlB.
Activation of NF- B by InlB may be part of the host defense response,
given that we have shown that InlB induces
NF- B-dependent inflammatory cytokine expression.
However, InlB may also be promoting an anti-apoptotic response required
for survival of L. monocytogenes-infected cells. This
response may require Akt, which, along with being involved in NF- B
activation, is also involved in phosphorylation and the inactivation of
the pro-apoptotic proteins Bad and pro-caspase 9 (22, 42-44). The
effect of Akt on NF- B has been shown to render cells partially
resistant to the pro-apoptotic effects of etoposide (39), supporting a
role for Akt/NF- B in any anti-apoptotic response to L. monocytogenes.
In conclusion, our results identify Ras and Akt as novel signals
activated by InlB, which are required for NF- B activation, with Ras
acting upstream of PI 3-kinase. Whether Ras and Akt are also required
for InlB-mediated internalization of L. monocytogenes is
under investigation, although, given that PI 3-kinase is required for
this process, there is a strong possibility that this will be the case.
These results concur with Met as the receptor for InlB and elucidate a
pathway important for the interaction between this bacterium and the
host cell.
 |
FOOTNOTES |
*
This work was supported in part by European Union Biomed 2 Program Grant BMH4-CT-97-2453 and by the Ministère de la
Recherche et de la Technologie Programme de Recherche Fondmentale en
Microbiologie et Maladies Infectieuses.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a short term EMBO fellowship.
International Scholar from the Howard Hughes Medical Institute.
**
To whom correspondence should be addressed: Dept. of Biochemistry
and Biotechnology Inst., Trinity College, Dublin D2, Ireland. Tel.:
353-1-608-2349; Fax: 353-1-677-2400; E-mail:
laoneill@tcd.ie.
Published, JBC Papers in Press, September 24, 2001, DOI 10.1074/jbc.M105202200
 |
ABBREVIATIONS |
The abbreviations used are:
InlA, internalin A;
InlB, internalin B;
PI 3-kinase, phosphoinositide 3-kinase;
HGF, hepatocyte growth factor;
RBD, Raf binding domain;
IKK, I B kinase;
NF- B, nuclear factor B;
FCS, fetal calf serum;
GST, glutathione
S-transferase;
PMSF, phenylmethylsulfonyl fluoride;
IL, interleukin;
PBS, phosphate-buffered saline;
PAGE, polyacrylamide gel
electrophoresis;
ELISA, enzyme-linked immunosorbent assay;
TK, thymidine kinase.
 |
REFERENCES |
| 1.
|
Dramsi, S.,
Lebrun, M.,
and Cossart, P.
(1996)
Curr. Top. Microbiol. Immunol.
209,
61-77[Medline]
[Order article via Infotrieve]
|
| 2.
|
Ireton, K.,
and Cossart, P.
(1997)
Annu. Rev. Genet.
31,
113-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Chakraborty, T.
(1999)
Immunobiology
201,
155-163[Medline]
[Order article via Infotrieve]
|
| 4.
|
Cossart, P.,
and Lecuit, M.
(1998)
EMBO J.
17,
3797-3806[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Dramsi, S.,
Biswas, I.,
Maguin, E.,
Braun, L.,
Mastroeni, P.,
and Cossart, P.
(1995)
Mol. Microbiol.
16,
251-261[Medline]
[Order article via Infotrieve]
|
| 6.
|
Braun, L.,
Dramsi, S.,
Dehoux, P.,
Bierne, H.,
Lindahl, G.,
and Cossart, P.
(1997)
Mol. Microbiol.
25,
285-294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Braun, L.,
Ohayon, H.,
and Cossart, P.
(1998)
Mol. Microbiol.
27,
1077-1087[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Braun, L.,
Nato, F.,
Payrastre, B.,
Mazie, J.-C.,
and Cossart, P.
(1999)
Mol. Microbiol.
34,
10-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Marino, M.,
Braun, L.,
Cossart, P.,
and Ghosh, P.
(1999)
Mol. Cell.
4,
1063-1072[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Ireton, K.,
Payrastre, B.,
Chap, H.,
Ogawa, W.,
Sakaue, H.,
Kasuga, M.,
and Cossart, P.
(1996)
Science
274,
780-782[Abstract/Free Full Text]
|
| 11.
|
Ireton, K.,
Payrastre, B.,
and Cossart, P.
(1999)
J. Biol. Chem.
274,
17025-17032[Abstract/Free Full Text]
|
| 12.
|
Braun, L.,
Ghebrehiwet, B.,
and Cossart, P.
(2000)
EMBO J.
19,
1458-1466[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Shen, Y.,
Naujokas, M.,
Park, M.,
and Ireton, K.
(2000)
Cell
103,
501-510[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Mansell, A.,
Braun, L.,
Cossart, P.,
and O'Neill, L. A. J.
(2000)
Cell Microbiol.
2,
127-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Schmidt, C.,
Bladt, F.,
Goedecke, S.,
Brinkmann, V.,
Zschiesche, W.,
Sharpe, M.,
Gherardi, E.,
and Birchmeler, C.
(1995)
Nature
373,
699-702[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Beg, A. A.,
and Baltimore, D.
(1996)
Science
274,
782-784[Abstract/Free Full Text]
|
| 17.
|
LaCasse, E. C.,
Baird, S.,
Korneluk, R. G.,
and MacKenzie, A. E.
(1998)
Mol. Cell. Biol.
19,
3247-3259
|
| 18.
|
Barkett, M.,
and Gilmore, T. D.
(1999)
Oncogene
18,
6910-6924[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Izquierdo, M.,
Leevers, S. J.,
Marshall, C. J.,
and Cantrell, D.
(1993)
J. Exp. Med.
178,
1199-1208[Abstract/Free Full Text]
|
| 20.
|
Bradford, M. M.
(1970)
Anal. Biochem.
72,
248-254[CrossRef]
|
| 21.
|
Mahon, T. M.,
and O'Neill, L. A. J.
(1995)
J. Biol. Chem.
270,
28557-28564[Abstract/Free Full Text]
|
| 22.
|
Marte, B. M.,
and Downward, J.
(1997)
Trends Biochem. Sci.
22,
355-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Wyllie, D. H.,
Kiss-Toth, E.,
Visintin, A.,
Smith, S. C.,
Boussouf, S.,
Segal, D. M.,
Duff, G. W.,
and Dower, S. K.
(2000)
J. Immunol.
165,
7125-7132[Abstract/Free Full Text]
|
| 24.
|
Hara, M.,
and Han, M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
3333-3337[Abstract/Free Full Text]
|
| 25.
|
Vlahos, C. J.,
Matter, W. F.,
Brown, R. F.,
Traynor-Kaplan, A. E.,
Heyworth, P. G.,
Prossnitz, E. R.,
Ye, R. D.,
Marder, P.,
Schelm, J. A.,
and Rothfuss, K. J.
(1995)
J. Immunol.
154,
2413-2422[Abstract]
|
| 26.
|
Franke, T. F.,
Kaplan, D. R.,
and Cantley, L. C.
(1997)
Cell
88,
435-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Downward, J.
(1998)
Curr. Opin. Cell Biol.
10,
262-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sizemore, N.,
Leung, S.,
and Stark, G. R.
(1999)
Mol. Cell. Biol.
19,
4798-4805[Abstract/Free Full Text]
|
| 29.
|
Reddy, S. A.,
Huang, J. H.,
and Liao, W. S.
(1997)
J. Biol. Chem.
272,
29167-29173[Abstract/Free Full Text]
|
| 30.
|
Romashkova, J. A.,
and Makarov, S. S.
(1999)
Nature
401,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Hu, Y.,
Qiao, L.,
Wang, S.,
Rong, S. B.,
Meuillet, E. J.,
Berggren, M.,
Gallegos, A.,
Powis, G.,
and Kozikowski, A. P.
(2000)
J. Med. Chem.
43,
3045-3051[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Hu, Y.,
Meuillet, E. J.,
Berggren, M.,
Powis, G.,
and Kozikowski, A. P.
(2001)
Bioorg. Med. Chem. Lett.
11,
173-176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Cossart, P.
(2001)
Trends Microbiol
9,
105-107[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Birchmeier, C.,
and Gherardi, E.
(1998)
Trends Cell Biol.
8,
404-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Ridley, A. J.,
Comoglio, P. M.,
and Hall, A.
(1995)
Mol. Cell. Biol.
15,
1110-1122[Abstract]
|
| 36.
|
Ponzetto, C.,
Bardelli, A.,
Maina, F.,
Longati, P.,
Panayotou, G.,
Dhand, R.,
Waterfield, M. D.,
and Comoglio, P. M.
(1993)
Mol. Cell. Biol.
13,
4600-4608[Abstract/Free Full Text]
|
| 37.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Vanhaesebroeck, B.,
Waterfield, M. D.,
and Downward, J.
(1996)
EMBO J.
15,
2442-2451[Medline]
[Order article via Infotrieve]
|
| 38.
|
Potempa, S.,
and Ridley, A. J.
(1998)
Mol. Biol. Cell
9,
2185-2200[Abstract/Free Full Text]
|
| 39.
|
Karin, M.
(1999)
Oncogene
18,
6867-6874[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Madrid, L. V.,
Wang, C. Y.,
Guttridge, D. C.,
Schottelius, A. J.,
Baldwin, A. S., Jr.,
and Mayo, M. W.
(2000)
Mol. Cell. Biol.
20,
1626-1638[Abstract/Free Full Text]
|
| 41.
|
Madrid, L. V.,
Mayo, M. W.,
Reuther, J. Y.,
and Baldwin, A. S., Jr.
(2001)
J. Biol. Chem.
276,
18934-18940[Abstract/Free Full Text]
|
| 42.
|
Datta, S. R.,
Brunet, A.,
and Greenberg, M. E.
(1999)
Genes Dev.
13,
2905-2927[Free Full Text]
|
| 43.
|
Datta, S. R.,
Dudek, H.,
Tao, X.,
Masters, S.,
Fu, H.,
Gotoh, Y.,
and Greenberg, M. E.
(1997)
Cell
91,
231-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Cardone, M. H.,
Roy, N.,
Stennicke, H. R.,
Salvesen, G. S.,
Franke, T. F.,
Stanbridge, E.,
Frisch, S.,
and Reed, J. C.
(1998)
Science
282,
1318-1321[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Noor, H. Goldfine, D. E. Tucker, S. Suram, L. L. Lenz, S. Akira, S. Uematsu, M. Girotti, J. V. Bonventre, K. Breuel, et al.
Activation of Cytosolic Phospholipase A2{alpha} in Resident Peritoneal Macrophages by Listeria monocytogenes Involves Listeriolysin O and TLR2
J. Biol. Chem.,
February 22, 2008;
283(8):
4744 - 4755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Reimer, M. Schweizer, and T. W. Jungi
Type I IFN Induction in Response to Listeria monocytogenes in Human Macrophages: Evidence for a Differential Activation of IFN Regulatory Factor 3 (IRF3)
J. Immunol.,
July 15, 2007;
179(2):
1166 - 1177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Li, M. Lorinczi, K. Ireton, and L. A. Elferink
Specific Grb2-mediated Interactions Regulate Clathrin-dependent Endocytosis of the cMet-tyrosine Kinase
J. Biol. Chem.,
June 8, 2007;
282(23):
16764 - 16775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lecuit, J. L. Sonnenburg, P. Cossart, and J. I. Gordon
Functional Genomic Studies of the Intestinal Response to a Foodborne Enteropathogen in a Humanized Gnotobiotic Mouse Model
J. Biol. Chem.,
May 18, 2007;
282(20):
15065 - 15072.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Lee, H. S. Lee, J. Jung, S. J. Cho, H.-Y. Chung, W. H. Kim, Y.-W. Jin, C. S. Kim, and S. Y. Nam
Nuclear Factor-{kappa}B Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer
Clin. Cancer Res.,
April 1, 2005;
11(7):
2518 - 2525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. F. Liu and Y. H. Wong
G16-mediated Activation of Nuclear Factor {kappa}B by the Adenosine A1 Receptor Involves c-Src, Protein Kinase C, and ERK Signaling
J. Biol. Chem.,
December 17, 2004;
279(51):
53196 - 53204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Segura, M. Gottschalk, and M. Olivier
Encapsulated Streptococcus suis Inhibits Activation of Signaling Pathways Involved in Phagocytosis
Infect. Immun.,
September 1, 2004;
72(9):
5322 - 5330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Takada, F. R. Khuri, and B. B. Aggarwal
Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-{kappa}B-regulated Gene Expression and Up-regulation of Apoptosis
J. Biol. Chem.,
June 18, 2004;
279(25):
26287 - 26299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Purushothaman, B. Wang, and P. P. Cleary
M1 Protein Triggers a Phosphoinositide Cascade for Group A Streptococcus Invasion of Epithelial Cells
Infect. Immun.,
October 1, 2003;
71(10):
5823 - 5830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dramsi and P. Cossart
Listeriolysin O-Mediated Calcium Influx Potentiates Entry of Listeria monocytogenes into the Human Hep-2 Epithelial Cell Line
Infect. Immun.,
June 1, 2003;
71(6):
3614 - 3618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. K. Brint, K. A. Fitzgerald, P. Smith, A. J. Coyle, J.-C. Gutierrez-Ramos, P. G. Fallon, and L. A. J. O'Neill
Characterization of Signaling Pathways Activated by the Interleukin 1 (IL-1) Receptor Homologue T1/ST2. A ROLE FOR JUN N-TERMINAL KINASE IN IL-4 INDUCTION
J. Biol. Chem.,
December 13, 2002;
277(51):
49205 - 49211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Meng, L. Liu, P. C. Chin, and S. R. D'Mello
Akt Is a Downstream Target of NF-kappa B
J. Biol. Chem.,
August 9, 2002;
277(33):
29674 - 29680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Bierne and P. Cossart
InlB, a surface protein of Listeria monocytogenes that behaves as an invasin and a growth factor
J. Cell Sci.,
January 9, 2002;
115(17):
3357 - 3367.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|